Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Digital health tools

Topic: Amyloid, tau and blood-test diagnosis

This bibliometric review examines the evolving landscape of artificial intelligence (AI) in neurodegenerative diseases research from 2000 to March 16, 2025, utilizing data from 1,402 publications (1,159 articles, 243 reviews) indexed in the Web of Science Core Collection. Through advanced tools - VOSviewer, CiteSpace, and Bibliometrix R - the study maps collaboration networks, keyword trends, and knowledge trajectories. Results reveal exponential growth post-2017, driven by advancements in deep learning and multimodal data integration. The United States (25.96%) and China (24.11%) dominate publication volume, while the UK exhibits the highest collaboration centrality (0.24) and average citations per publication (31.68). Core journals like Scientific Reports and Frontiers in Aging Neuroscience published the most articles in this field. Highly cited publications and burst references highlight important milestones in the development history. High-frequency keywords include “alzheimer’s disease,” “parkinson’s disease,” “magnetic resonance imaging,” “convolutional neural network,” “biomarkers,” “dementia,” “classification,” “mild cognitive impairment,” “neuroimaging,” and “feature extraction.” Key hotspots include intelligent neuroimaging analysis, machine learning methodological iterations, molecular mechanisms and drug discovery, and clinical decision support systems for early diagnosis. Future priorities encompass advanced deep learning architectures, multi-omics integration, explainable AI systems, digital biomarker-based early detection, and transformative technologies including transformers and telemedicine. This analysis delineates AI’s transformative role in optimizing diagnostics and accelerating therapeutic innovation, while advocating for enhanced interdisciplinary collaboration to bridge computational advances with clinical translation.

Key findings

Why it matters

This is a count of publications about artificial intelligence in neurodegenerative disease research, showing that output grew quickly after 2017 and that the United States and China produced the most papers. It reports no treatment, cure, or prevention effect for Alzheimer's disease.

Study details

How this study scored 43/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 41 of the 96 points it could be judged on, which is 43 of 100. Total 43 of 100.41 of the 96 points we could judge = 43 of 100

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 41 of the 96 points we could judge it on, which is 43 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in Neurology)
Journal's citation record 2 / 4 Frontiers in Neurology: journal h-index 162 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 13 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.3 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 8.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Qi Guo holds only 4 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Chinese People's Liberation Army: institution h-index 333 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40771972)
Free to read 2 / 2 Free to read
Points 41 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 41 of the 96 points we could judge it on is 43 out of 100.
Total 43 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Zhang, Y., Yu, L., Lv, Y., Yang, T., & Guo, Q. (2025). Artificial intelligence in neurodegenerative diseases research: a bibliometric analysis since 2000. Frontiers in Neurology. https://doi.org/10.3389/fneur.2025.1607924

Vancouver

Zhang Y, Yu L, Lv Y, Yang T, Guo Q. Artificial intelligence in neurodegenerative diseases research: a bibliometric analysis since 2000. Frontiers in Neurology. 2025. doi:10.3389/fneur.2025.1607924. PMID: 40771972.

BibTeX

@article{zhang2025-40771972,
  author  = {Zhang, Yabin and Yu, Lei and Lv, Yuting and Yang, Tiantian and Guo, Qi},
  title   = {{Artificial intelligence in neurodegenerative diseases research: a bibliometric analysis since 2000}},
  journal = {Frontiers in Neurology},
  year    = {2025},
  doi     = {10.3389/fneur.2025.1607924},
  pmid    = {40771972},
  url     = {https://doi.org/10.3389/fneur.2025.1607924}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Digital health tools

Similar studies

More on Digital health tools

See all studies in Digital health tools →